Trial Profile

Study Describing The Patient Outcome In Multiple Myeloma Refractory To CD38 MoABs

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 09 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Carfilzomib (Primary) ; Daratumumab (Primary) ; Isatuximab (Primary)
Indications Multiple myeloma
Focus Therapeutic Use
Acronyms MAMMOTH

Most Recent Events

01 May 2022 Results from CARTITUDE-1 and MAMMOTH comparing Ciltacel Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma ,published in the Clinical Lymphoma, Myeloma & Leukemia
14 Dec 2021 Results presented at the 63rd American Society of Hematology Annual Meeting and Exposition
17 Jun 2021 Results presented at the 26th Congress of the European Haematology Association

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com